Effect of Combining Ivabradine and ?-Blockers: Focus on the Use of Carvedilol in the SHIFT Population

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33157491" target="_blank" >RIV/61989592:15110/15:33157491 - isvavai.cz</a>

Výsledek na webu

<a href="http://Effect" target="_blank" >http://Effect</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000380812" target="_blank" >10.1159/000380812</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of Combining Ivabradine and ?-Blockers: Focus on the Use of Carvedilol in the SHIFT Population

Popis výsledku v původním jazyce

OBJECTIVES: We explored the prescription of ?-blockers with ivabradine in patients with systolic heart failure, focusing on the most frequently coprescribed ?-blocker, carvedilol. METHODS: We analyzed outcomes in SHIFT patients with systolic heart failure who were prescribed ?-blockers (carvedilol, bisoprolol, metoprolol, or nebivolol) with ivabradine or placebo. Analysis was by intention to treat in patients prescribed a ?-blocker at the time of the event. RESULTS: Data were available for 2,596 patients receiving carvedilol, 1,483 bisoprolol, 1,424 metoprolol, and 197 nebivolol. Mean treatment duration was 19 months. There was no difference in the effect of ivabradine on the primary composite endpoint of cardiovascular death or heart failure hospitalization between the various ?-blockers [hazard ratios (HR) for risk reduction, 0.75-0.89; p for interaction=0.86]. Patients prescribed carvedilol with ivabradine had lower rates of primary composite endpoint (HR 0.80, 95% CI: 0.68-0.94), h

Název v anglickém jazyce

Effect of Combining Ivabradine and ?-Blockers: Focus on the Use of Carvedilol in the SHIFT Population

Popis výsledku anglicky

OBJECTIVES: We explored the prescription of ?-blockers with ivabradine in patients with systolic heart failure, focusing on the most frequently coprescribed ?-blocker, carvedilol. METHODS: We analyzed outcomes in SHIFT patients with systolic heart failure who were prescribed ?-blockers (carvedilol, bisoprolol, metoprolol, or nebivolol) with ivabradine or placebo. Analysis was by intention to treat in patients prescribed a ?-blocker at the time of the event. RESULTS: Data were available for 2,596 patients receiving carvedilol, 1,483 bisoprolol, 1,424 metoprolol, and 197 nebivolol. Mean treatment duration was 19 months. There was no difference in the effect of ivabradine on the primary composite endpoint of cardiovascular death or heart failure hospitalization between the various ?-blockers [hazard ratios (HR) for risk reduction, 0.75-0.89; p for interaction=0.86]. Patients prescribed carvedilol with ivabradine had lower rates of primary composite endpoint (HR 0.80, 95% CI: 0.68-0.94), h

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiology

ISSN

0008-6312

e-ISSN

—

Svazek periodika

131

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

218-224

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—